All That Glitters: Bristol/Merck's Muraglitazar Will Be Pargluva
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies release Phase II and III data for the dual PPAR agonist at the American Diabetes Association annual meeting. Pargluva showed a statistically significant difference in reduction of A1C levels versus Lilly/Takeda's Actos in type 2 diabetes patients in the 24-week Phase III trial.
You may also be interested in...
Bristol's Abatacept, Muraglitazar To Go Before Advisory Committees In September
Orencia (abatacept) for moderately to severely active rheumatoid arthritis will be reviewed by FDA's Arthritis Drugs Advisory Commmittee. Pargluva (muraglitazar) will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee for type II diabetes mellitus.
Bristol's Abatacept, Muraglitazar To Go Before Advisory Committees In September
Orencia (abatacept) for moderately to severely active rheumatoid arthritis will be reviewed by FDA's Arthritis Drugs Advisory Commmittee. Pargluva (muraglitazar) will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee for type II diabetes mellitus.
AstraZeneca Galida NDA Delayed Until 2007 Due To PPAR Safety Concerns
AstraZeneca will delay an NDA filing for its dual PPAR Galida (tesaglitazar) until 2007 in order to gather two years of long-term follow-up data